A CPFT-led research group has won over $3 million to expand studies investigating biomarkers and brain changes in Alzheimer’s disease, to progress treatments for adults with Down’s syndrome who are most at risk.
Their ongoing research programme published results in The Lancet this summer, revealing that the cognitive and biochemical changes in Alzheimer’s disease start more than 20 years before clinical symptoms present in people with Down’s syndrome.
In middle age, many people with Down’s syndrome start to develop problems with memory and thinking linked with these changes. Imaging biomarkers show that a long preclinical phase follows a predictable sequence, similar to the development of Alzheimer’s disease in the general population.
The Cambridge Intellectual and Developmental Disabilities Research Group (CIDDRG), led by CPFT consultant psychiatrist and researcher Dr Shahid Zaman, has been awarded $3.4 million by the National Institutes of Health in the United States (NIH-US) to continue this research.
The CIDDRG partners the UK with an international consortium of 12 specialist research centres awarded a total $106 million over five years to work towards interrupting this sequence and preventing dementia.
Shahid (pictured left) said: “This is wonderful news for people with Down’s syndrome and researchers and clinicians working to help them. This award and research programme will help to advance targeted and well-designed clinical trials for people with Down’s syndrome and address mortality risk from dementia for this vulnerable group.
“I commend the NIH for making a visionary and ambitious decision, and am honoured to be leading the expert research team in Cambridge contributing to the international effort.
The data generated by this large scale research programme will boost the development of preventive treatments for dementia.”
The CIDDRG has been closely monitoring a group of participants with Down’s syndrome, who did not have a diagnosis of dementia at the start of the programme.
They have been able to track how people change from being asymptomatic to developing dementia, using measurements including memory and thinking tests and brain scans detecting the presence of abnormal protein deposits (amyloid and tau) in the brain, associated with Alzheimer’s disease.
Under the NIH programme, research teams will assess and examine a wide range of data from plasma-based biomarkers to biofluids, genetic factors, neuroimaging and everyday cognitive and psychological functioning. Research participants will be seen every 16 months for up to four visits.
For more information, visit: https://www.nia.nih.gov/health/abc-ds-information-patients-and-families.
This research will be funded by NIH grant U19AG068054.
The CIDDRG is also supported in the UK by the Medical Research Council, the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the East of England (now the NIHR Applied Research Collaboration East of England), the NIHR Cambridge Dementia Biomedical Research Unit, the Down Syndrome Association, and the Health Foundation.